LUNG CANCER

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression

Retrieved on: 
Thursday, March 17, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, EORTC, ETOP, Lung Cancer, Merck’s Research in Lung Cancer, Merck’s Early-Stage Cancer Clinical Program, Merck, EORTC, ETOP, LUNG CANCER, MERCK’S RESEARCH IN LUNG CANCER, MERCK’S EARLY-STAGE CANCER CLINICAL PROGRAM, MERCK

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 82% of all cases.

Key Points: 
  • Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 82% of all cases.
  • In the U.S., the overall five-year survival rate for patients diagnosed with lung cancer is 24%, a 14% improvement over the last five years.
  • Among Mercks research efforts are trials focused on evaluating KEYTRUDA in earlier stages of lung cancer as well as identifying new combinations and coformulations with KEYTRUDA.
  • Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.

New Data Suggest Veracyte’s Percepta Genomic Sequencing Classifier Can Help Accelerate Timely Treatment for Patients with Early-Stage Lung Cancer

Retrieved on: 
Monday, January 24, 2022
Surgery, Hospitals, Genetics, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Oncology, Pulmonology, Patient, ROM, Bronchoscopy, Interventional pulmonology, BioMed Central, TTEC, GSC, Decision-making, Malignancy, BMC, Cleveland Clinic, Diagnosis, Paper, FCCP, Guideline, Physician, Risk, Lung cancer, Medical imaging, Pharmaceutical industry, the Percepta Genomic Sequencing Classifier (GSC), Lung Cancer, Veracyte, THE PERCEPTA GENOMIC SEQUENCING CLASSIFIER (GSC), LUNG CANCER, VERACYTE

Veracyte, Inc. (Nasdaq: VCYT) announced the publication of new data that suggest the companys Percepta Genomic Sequencing Classifier (GSC) can accelerate delivery of curative therapy for patients with high-risk lung nodules and inconclusive bronchoscopy results.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) announced the publication of new data that suggest the companys Percepta Genomic Sequencing Classifier (GSC) can accelerate delivery of curative therapy for patients with high-risk lung nodules and inconclusive bronchoscopy results.
  • Veracyte developed the Percepta GSC to aid in the diagnosis of patients who have suspicious lung nodules and inconclusive bronchoscopy results.
  • The Percepta GSC stratifies the risk of primary lung cancer to guide patient management when bronchoscopy is inconclusive.
  • Examples of forward-looking statements include, among others, statements regarding Veracytes belief that its Percepta Genomic Classifier can improve the diagnosis of lung cancer, and assist healthcare providers in making treatment decisions.

Merck’s KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression

Retrieved on: 
Monday, January 10, 2022
Oncology, Medical Supplies, Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, KEYNOTE-091/EORTC-1416-LCG – PEARLS, EORTC, ETOP, Lung Cancer, Merck’s Early-Stage Cancer Clinical Program, Merck, KEYNOTE-091/EORTC-1416-LCG – PEARLS, EORTC, ETOP, LUNG CANCER, MERCK’S EARLY-STAGE CANCER CLINICAL PROGRAM, MERCK

We are encouraged by these results supporting the potential role of KEYTRUDA in stage IB-IIIA non-small cell lung cancer.

Key Points: 
  • We are encouraged by these results supporting the potential role of KEYTRUDA in stage IB-IIIA non-small cell lung cancer.
  • The results from KEYNOTE-091 are a first for KEYTRUDA in the adjuvant treatment setting in patients with stage IB-IIIA NSCLC.
  • Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all cases.
  • Selected KEYTRUDA (pembrolizumab) Indications in the U.S.
    KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.

New Data From the Phase II CITYSCAPE Trial Show Encouraging Results With Genentech’s Novel Anti-TIGIT Tiragolumab Plus Tecentriq

Retrieved on: 
Friday, December 10, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Oncology, Risk, Neoplasm, Population, Patient, Immunotherapy, Pain, ESMO, European Society for Medical Oncology, Phase, TPS, PFS, AES, Safety, Lung cancer, Progression-free survival, Pros, Quality of life, Food, Death, ROG, Lung, Rash, Cancer, Breathe Me, RO, Fatigue, EORTC, Breakthrough therapy, BTD, Esophageal cancer, Hematological Cancer Research Investment and Education Act, Abstract, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hoffmann-La Roche, NE, NSCLC, OS, ITT, Pharmaceutical industry, the CITYSCAPE study1, tiragolumab, lung cancer, Tecentriq® (atezolizumab), Genentech in cancer immunotherapy, Genentech in lung cancer, Genentech, THE CITYSCAPE STUDY1, TIRAGOLUMAB, LUNG CANCER, TECENTRIQ® (ATEZOLIZUMAB), GENENTECH IN CANCER IMMUNOTHERAPY, GENENTECH IN LUNG CANCER, GENENTECH

After 2.5 years median follow-up, tiragolumab plus Tecentriq continued to show an improvement in the intention-to-treat (ITT) population (n=67), driven by the PD-L1-high population (TPS 50%) (n=29).

Key Points: 
  • After 2.5 years median follow-up, tiragolumab plus Tecentriq continued to show an improvement in the intention-to-treat (ITT) population (n=67), driven by the PD-L1-high population (TPS 50%) (n=29).
  • Since 2020, Genentech has initiated five Phase III trials evaluating tiragolumab plus Tecentriq in early and metastatic disease in lung (SKYSCRAPER-01, SKYSCRAPER-02, SKYSCRAPER-03) and esophageal cancers (SKYSCRAPER-07, SKYSCRAPER-08).
  • CITYSCAPE is a global Phase II, randomized and blinded study evaluating tiragolumab plus Tecentriq (atezolizumab) compared with Tecentriq alone in 135 patients with first-line PD-L1-positive locally advanced, unresectable or metastatic non-small cell lung cancer.
  • Patients were randomized 1:1 to receive either tiragolumab plus Tecentriq or placebo plus Tecentriq, until progressive disease or loss of clinical benefit.

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) ISSUES POSITIVE RECOMMENDATION FOR TAGRISSO® ▼ (osimertinib) IN ENGLAND FOR PATIENTS WITH EARLY-STAGE LUNG CANCER

Retrieved on: 
Tuesday, November 30, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, osimertinib, lung cancer, OSIMERTINIB, LUNG CANCER

Data show that osimertinib, a well-tolerated treatment, reduces the risk of cancer recurrence or death by 80% in patients with early-stage EGFR mutation-positive non-small cell lung cancer after a successful operation.

Key Points: 
  • Data show that osimertinib, a well-tolerated treatment, reduces the risk of cancer recurrence or death by 80% in patients with early-stage EGFR mutation-positive non-small cell lung cancer after a successful operation.
  • It is a third generation, orally administered EGFR TKI, a targeted therapy for advanced EGFR mutation-positive NSCLC.
  • Patients were treated with osimertinib 80mg once-daily oral tablets or placebo for three years or until disease recurrence.
  • The primary endpoint was DFS in Stage II and IIIA patients and a key secondary endpoint was DFS in Stage IB, II and IIIA patients.

EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa

Retrieved on: 
Monday, November 22, 2021
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, 1World, International Agency for Research on Cancer, NSCLC, Lung cancer, Esophageal cancer, TKI, Form, NMPA, APOLLO, New Drug Application, Prospectus, Risk, National Medical Products Administration, LinkedIn, Jameel, PD-L1, Organic, SEC filing, Social media, Catalog, Stomach, Failure, Method, Research, Sale, PIPE, Forward-looking statement, Large-cell lung carcinoma, Xi, Immunoglobulin G, Progression-free survival, Twitter, FDA, Ix, Growth, Securities Act of 1933, Patient, Adoption, Technology, Toxic Substances Control Act of 1976, Madison Avenue, EGFR, SEC, Proxy, Communication, Instagram, Antibody, III, Name, Disease, Pharmaceutical industry, Book, Lung Cancer, Aumolertinib, Sugemalimab, EQRx, LUNG CANCER, AUMOLERTINIB, SUGEMALIMAB, EQRX

Through the agreement, Abdul Latif Jameel Health will become EQRxs regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.

Key Points: 
  • Through the agreement, Abdul Latif Jameel Health will become EQRxs regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.
  • Its our joint mission with EQRx to change that, a mission that is aligned with the values of the Jameel Family.
  • Aumolertinib is a novel, irreversible EGFR-TKI that selectively inhibits both EGFR sensitizing and resistance mutations with high selectivity over wild-type EGFR.
  • EQRx and Remaking Medicine are trademarks of EQRx, Inc.
    1World Health Organization, International Agency for Research on Cancer.

Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer

Retrieved on: 
Monday, November 22, 2021
Research, Clinical Trials, Biotechnology, Other Health, Health, General Health, Other Science, Science, Oncology, Patient, NSCLC, Skin, Pemetrexed, Pancreatic cancer, Docetaxel, Mesothelioma, Ovarian cancer, Disease, Lung cancer, Annual report, Private Securities Litigation Reform Act, Forward-looking statement, Alternating electric field therapy, Toxicity, Large-cell lung carcinoma, Courage, Cancer, Non-small-cell lung carcinoma, Neoplasm, Physician, COVID-19, Glioblastoma, U.S. Securities and Exchange Commission, Liver cancer, Survival, Twitter, Treatment of lung cancer, Adult, Radiation, Immunotherapy, LinkedIn, Stomach, NASDAQ, Fundamental, Standard of care, Pharmaceutical industry, Lung Cancer, Tumor Treating Fields, Novocure, LUNG CANCER, TUMOR TREATING FIELDS, NOVOCURE

Non-small cell lung cancer impacts nearly 200,000 patients every year in the U.S., and lung cancer is the leading cause of cancer-related death globally.

Key Points: 
  • Non-small cell lung cancer impacts nearly 200,000 patients every year in the U.S., and lung cancer is the leading cause of cancer-related death globally.
  • LUNAR will provide the first randomized dataset to evaluate increased survival when Tumor Treating Fields is used together with immunotherapy, versus immunotherapy alone.
  • Lung cancer is the most common cause of cancer-related death worldwide, and NSCLC accounts for approximately 85% of all lung cancers.
  • Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

FDA Approves Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer

Retrieved on: 
Friday, October 15, 2021
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Orbis, ROG, Death, Immune system, Lung, PD-L1, PD-1, Safety, Lung cancer, FDA, Disease, Pneumonitis, Regulation of tobacco by the U.S. Food and Drug Administration, Fever, American Cancer Society, Paclitaxel, Patient, Carboplatin, Platinum, Risk, Cancer, Tissue, Hoffmann-La Roche, Breast, Phase, Food, NSCLC, ITT, Immunotherapy, Hope, Human, BSC, Diagnosis, Etoposide, Treatment of lung cancer, Physician, PD, United Kingdom, Skin, Neoplasm, UICC, Bevacizumab, RO, Pneumonia, Head, Toxicity, SCLC, Recurrence, DFS, Review, Pharmaceutical industry, Medical imaging, Vaccine, Health insurance, Uranium, the IMpower010 study, lung cancer, Tecentriq® (atezolizumab), Genentech in cancer immunotherapy, Genentech in lung cancer, Genentech, THE IMPOWER010 STUDY, LUNG CANCER, TECENTRIQ® (ATEZOLIZUMAB), GENENTECH IN CANCER IMMUNOTHERAPY, GENENTECH IN LUNG CANCER, GENENTECH

Tecentriq has previously shown clinically meaningful benefit in various types of lung cancer, with six currently approved indications in the U.S.

Key Points: 
  • Tecentriq has previously shown clinically meaningful benefit in various types of lung cancer, with six currently approved indications in the U.S.
  • In addition to becoming the first approved cancer immunotherapy for adjuvant NSCLC, Tecentriq was also the first approved cancer immunotherapy for front-line treatment of adults with extensive-stage small cell lung cancer (SCLC) in combination with carboplatin and etoposide (chemotherapy).
  • According to the American Cancer Society, it is estimated that more than 235,000 Americans will be diagnosed with lung cancer in 2021.
  • Today, about half of all people with early lung cancer still experience a cancer recurrence following surgery.

Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test’s Ability to Improve Early Lung Cancer Assessment

Retrieved on: 
Monday, October 11, 2021
Oncology, Medical Supplies, Health, Medical Devices, Clinical Trials, Research, Science, Twitter, Lung, Forward-looking statement, CT, Patient, Large-cell lung carcinoma, Health, Risk, Idiopathic pulmonary fibrosis, GSC, Kidney, American College of Chest Physicians, PPV, NanoString Technologies, Lung cancer, Breast cancer, Physician, Form 10-Q, Prostate cancer, Investor, NSCLC, Diagnosis, Cancer, Population, Annual report, SEC, NPV, Smoker, Medical Center, Lahey Hospital & Medical Center, Medical college, Bladder cancer, AnMed Health Medical Center, American College, Technology, Medical College of Wisconsin, Thyroid cancer, Annual general meeting, Medical imaging, Lung Cancer, Veracyte, LUNG CANCER, VERACYTE

(Nasdaq: VCYT) today announced that new expanded clinical validation data reinforce the ability of the companys noninvasive Percepta Nasal Swab test to help physicians more accurately assess lung cancer risk in patients with lung nodules.

Key Points: 
  • (Nasdaq: VCYT) today announced that new expanded clinical validation data reinforce the ability of the companys noninvasive Percepta Nasal Swab test to help physicians more accurately assess lung cancer risk in patients with lung nodules.
  • Veracyte also announced it has begun making the Percepta Nasal Swab test available to a limited number of clinical sites as it builds the clinical utility data to support reimbursement.
  • Our findings reinforce the Percepta Nasal Swab tests ability to more accurately identify patients as low, moderate or high risk for lung cancer so that physicians can make more confident decisions about next steps for their patients.
  • The Percepta Nasal Swab tests robust performance in classifying lung cancer risk was previously demonstrated in a blinded, independent validation set of 249 patients from multiple cohorts comprising prospectively collected nasal samples.

New Phase III Data Support the Benefit of Genentech’s Tecentriq in Early-stage Lung Cancer

Retrieved on: 
Monday, September 20, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, ITT, Safety, Food, Oncology, Nominal interest rate, Neoplasm, Breast, WCLC, RO, Treatment of lung cancer, Carboplatin, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Recurrence, Congress, Conference, SCLC, FDA, Guideline, Cancer, Lung cancer, Hoffmann-La Roche, European Society for Medical Oncology, Population, ROG, Head, Immune system, DFS, Phase, NSCLC, Death, Stage, International Association, PD-1, Large-cell lung carcinoma, Paclitaxel, Disease, Risk, Bevacizumab, PD, BSC, Priority review, American Cancer Society, Etoposide, PD-L1, Tissue, Platinum, ESMO, UICC, Skin, Lung, Pharmaceutical industry, Health insurance, Medical imaging, Uranium, Vaccine, the IMpower010 study, lung cancer, Tecentriq® (atezolizumab), Genentech in cancer immunotherapy, Genentech in lung cancer, Genentech, THE IMPOWER010 STUDY, LUNG CANCER, TECENTRIQ® (ATEZOLIZUMAB), GENENTECH IN CANCER IMMUNOTHERAPY, GENENTECH IN LUNG CANCER, GENENTECH

Safety data for Tecentriq were consistent with its known safety profile and no new safety signals were identified.

Key Points: 
  • Safety data for Tecentriq were consistent with its known safety profile and no new safety signals were identified.
  • IMpower010 shows how, for the first time, a cancer immunotherapy may help many of these patients live longer without their disease returning.
  • The data presented at ESMO and WCLC further contribute to our understanding of Tecentriq in this treatment setting.
  • Tecentriq has previously shown clinically meaningful benefit in various types of lung cancer, with five currently approved indications in markets around the world.